LGND241220C175000
- 0.00
- 0.000.00%
Ligand Pharmaceuticals Newsroom
Insider Sale: Chief Financial Officer of $LGND (LGND) Sells 2,104 Shares
Earnings Grew Faster Than the Notable 60% Return Delivered to Ligand Pharmaceuticals (NASDAQ:LGND) Shareholders Over the Last Year
Benchmark Co. Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $135
Ligand Pharmaceuticals Is Maintained at Overweight by Barclays
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $160
Ligand Pharmaceuticals Is Maintained at Outperform by RBC Capital
Craig-Hallum Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating
Oppenheimer Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $151
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $143
H.C. Wainwright Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $157
Ligand Pharmaceuticals Issues 2025 Guidance; 2024 Forecast Reaffirmed
Ligand Pharmaceuticals Investor And Analyst Day At 10:30 AM ET
Ligand Pharmaceuticals Sees 2025 Adj EPS $6.00-Adj EPS $6.25 >LGND
Express News | Ligand Pharmaceuticals Inc -2025 Full Year Revenue Guidance of $180 Mln to $200 Mln
Express News | Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
Catalyst Watch: Goldman Sachs Finance Conference; Adobe, CostCo Earnings
RBC Capital Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Raises Target Price to $141
Insider Sale: Director at $LGND (LGND) Sells 2,406 Shares
Selling US$6.3m Of Stock Was Lucrative Decision For Ligand Pharmaceuticals Insiders
Barclays Maintains Ligand Pharmaceuticals(LGND.US) With Buy Rating, Maintains Target Price $150